Researchers at 13 VA medical centers nationwide are conducting a collaborative, placebo-controlled trial of the medication prazosin. They hope to enroll 320 veterans with war-zone, trauma-induced PTSD. They will compare the efficacy of prazosin or a placebo on nightmares, sleep disturbance, and global clinical status for 10 weeks; they will assess the same outcome measures after 16 additional weeks of maintenance treatment. They also will study prazosin's long-term impact, compared with that of the placebo, on total PTSD symptoms, comorbid depression, quality of life, and physical functioning.